A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion. In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C. In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C. People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie diagnoza nowotworu złośliwego żołądka, przełyku, trzustki, dróg żółciowych, okrężnicy, płuc, jajnika lub piersi
- •Potwierdzony obrazowo zaawansowany nowotwór w ciągu 28 dni przed rozpoczęciem badania
- •Mierzalne ogniska nowotworu widoczne w badaniach obrazowych (w niektórych grupach badania)
- •Nowotwór wykazuje białko CLDN18.2
- •Wcześniejsze leczenie systemeowe z powodu zaawansowanego nowotworu (co najmniej jedno leczenie)
- •Ogólny stan zdrowia oceniony na 0 lub 1 (zdolność do wykonywania codziennych czynności)
- •Przewidywana długość życia co najmniej 12 tygodni
- •Kobieta: nie w ciąży, niepłodna lub potwierdzona ujemna próba ciążowa przy zgodzie na antykoncepcję przez okres badania i 6 miesięcy po
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (14)
UAB Medicine - UAB Hospital
Birmingham, United States
START Los Angeles
Los Angeles, United States
Indiana University (IU) Health - Multi-D Oncology Clinic
Indianapolis, United States
START Midwest
Grand Rapids, United States
START New York
Lake Success, United States
Duke Cancer Center Durham
Durham, United States
Next Oncology - Austin
Austin, United States
Next Oncology - Houston
Houston, United States
Next Oncology - Dallas
Irving, United States
START San Antonio
San Antonio, United States
START Mountain Region
West Valley City, United States
National Cancer Center Hospital East
Kashiwa-shi, Japan
National Cancer Center Hospital
Chuo-ku, Japan
The Cancer Institute Hospital of JFCR
Koto-ku, Japan
Trial contact
Astellas Pharma Global Development, Inc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.